EP Patent

EP0407122B1 — Novel modified PF4 compositions and methods of use

Assigned to Repligen Corp · Expires 1996-10-02 · 30y expired

What this patent protects

A polypeptide conjugate comprising platelet factor 4 (PF4), or an angiogenesis-inhibiting fragment or mutant thereof, conjugated to a second molecule, is useful in diagnosis.

USPTO Abstract

A polypeptide conjugate comprising platelet factor 4 (PF4), or an angiogenesis-inhibiting fragment or mutant thereof, conjugated to a second molecule, is useful in diagnosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP0407122B1
Jurisdiction
EP
Classification
—
Expires
1996-10-02
Drug substance claim
No
Drug product claim
No
Assignee
Repligen Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.